Current chemotherapies for advanced hepatocellular carcinoma

Nouso, Kazuhiro

doi:10.1007/s12328-013-0363-4

Cited by 2 publications

(3 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In China, HCC causes ~110,000 deaths annually (2). Current chemotherapeutic drugs for treating HCC are restricted in their clinical application because of toxicity and low efficacy (3,4). Arsenic trioxide (As 2 O 3 ) (1-8 µM) arrests HCC (HepG2 and SMMC-7721 cells) in the G 2 /M phase (5).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

(+)-Terrein inhibits human hepatoma Bel-7402 proliferation through cell cycle arrest

et al. 2015

View full text Add to dashboard Cite

Hepatoma is a common malignant tumor. Thus, the development of a high‑efficacy therapeutic drug for hepatoma is required. In this study, (+)‑terrein isolated from the marine sponge‑derived Aspergillus terreus PF‑26 against cell growth, apoptosis and cell cycle were assessed by MTT and flow cytometry. mRNA array containing 73 cell cycle‑related genes and three cell morphology‑related genes was generated and its performance evaluated. The cell cycle pathway map was created using the pathview package. The results showed that (+)‑terrein inhibited the growth of Bel‑7402 cells with alterations in cell morphology and a reduced transcript expression of cell morphology genes (fibronectin, N‑cadherin, and vimentin). In addition, flow cytometric analysis revealed that (+)‑terrein arrested the Bel‑7402 cell cycle without inducing apoptosis. Based on multiple mRNA analysis, the downregulated expression of the CCND2, CCNE2, CDKN1C, CDKN2B, ANAPC, PKMYT1, CHEK2 and PCNA genes was observed in 10 µM (+)‑terrein‑treated Bel‑7402 cells (>2‑fold and P≤0.05), compared with the controls. Thus, the antiprolife-rative mechanism of (+)‑terrein against Bel‑7402 cells may be due to the cell cycle arrest by blocking cell cycle gene expression and changing cell morphology.

show abstract

Section: Introductionmentioning

confidence: 99%

“…However, applications there of are controversial as arsenic compounds exhibit high toxicity. Therefore, developing a novel high-efficacy therapeutic drug for hepatoma is required (4). In 1935, Raistrick and Smith (6) first isolated (+)-terrein from Aspergillus terreus.…”

Section: Introductionmentioning

confidence: 99%

(+)-Terrein inhibits human hepatoma Bel-7402 proliferation through cell cycle arrest

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Both 5-FU, a pyrimidine analogue antimetabolite, and IFN, which influences the JAK-STAT pathway, have successfully been used in HCC [19]. In addition to its cytostatic effects, 5-FU facilitates T- and natural killer (NK) cell cytotoxicity by reducing the population of MDSCs [20].…”

Section: Introductionmentioning

confidence: 99%

Early Experiences with Triple Immunochemotherapy in Adolescents and Young Adults with High-Risk Fibrolamellar Carcinoma

et al. 2021

View full text Add to dashboard Cite

Introduction: There are no standard systemic therapies for the treatment of fibrolamellar carcinoma (FLC), as surgery remains the only definitive option. We share our experiences using systemic “triple therapy” (TT) with 5-fluorouracil, interferon, and nivolumab for the treatment of relapsed, refractory, metastatic, or unresectable FLC. Methods: Data from all patients who received TT from May 2018 to July 2020 were reviewed to assess response, survival, and toxicity. Results: A total of 22 patients were treated with TT, of which 14 (median age of 21 years) were evaluable. They received a median of 18 cycles (8–44). At the time of analysis, the median progression-free survival was 9 months (4.5–26), 29% longer than prior to TT, with 5 patients achieving clinical remission, 8 patients stable or improving, and 1 progression. Overall objective response (clinical remission + partial response) was 50% and tumor control rate (clinical remission + partial response + stable disease) was 93%. Two patients withdrew from treatment due to side effects. Discussion/Conclusion: Our early results support TT as a promising medical option to slow disease progression and prolong survival in high-risk patients with FLC. TT can be administered in the outpatient setting and has shown good tolerability. Further longitudinal data is needed to confirm outcomes, especially in patients still early in their treatment.

show abstract

Current chemotherapies for advanced hepatocellular carcinoma

Cited by 2 publications

References 51 publications

(+)-Terrein inhibits human hepatoma Bel-7402 proliferation through cell cycle arrest

(+)-Terrein inhibits human hepatoma Bel-7402 proliferation through cell cycle arrest

Early Experiences with Triple Immunochemotherapy in Adolescents and Young Adults with High-Risk Fibrolamellar Carcinoma

Contact Info

Product

Resources

About